Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials
Conclusions Phase 1 trials may offer similar or better clinical outcome for mCRC patients than standard third line therapies; the prognostic model could assist in selecting appropriate patients.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Bilirubin | Cancer | Cancer & Oncology | Colorectal Cancer | Drugs & Pharmacology | Investigational New Drugs | Toxicology